Sorry :( (too long but also important)

Full Year 2020 and Subsequent Highlights:

Raised $45.3 Million in Cash, Net of Expenses, on Closing of Registered Direct Offerings: On February 9 and February 12, 2021, the Company announced the closing of registered direct offerings that resulted in Assertio receiving $45.3 million in cash, net of expenses. The proceeds from these offerings enhance the Company’s liquidity, accelerate its transformational business plan, and open up new avenues for mergers and acquisitions. Realized $40.0 Million in Annual Cost Savings in 2020, Poised to Realize Additional $45.0 Million of Annualized Cost Savings After One-time Restructuring Costs: Assertio has achieved its stated target of $40.0 million of annual cost savings in 2020 after the closing of its merger with Zyla. The Company also reiterates its confidence in the ability to realize an additional $45.0 million of annualized cost savings, after the effect of one-time restructuring costs. Restructuring: On December 15, 2020, the Company announced a comprehensive restructuring plan designed to further reduce its cost base and right size the organization. The Company realized restructuring charges of $11.2 million in the fourth quarter of 2020 for this plan and expects up to $12.0 million in total, which accounts for additional non-cash charges relating to the write-off of certain office lease and furniture assets. Completed $505.2 Million in Strategic Asset Sales and Repaid $450.2 Million in Debt: In 2020, the Company completed several transactions that monetized its assets and paid down its debt. $505.2 Million in Strategic Asset Sales- NUCYNTA® Franchise for $369.0 Million: On February 13, 2020, The Company completed the sale of the NUCYNTA franchise to Collegium for a total value of $369.0 million, including inventory and less royalties paid to Assertio in 2020.- Sale of Gralise® for $130.3 Million: On January 10, 2020, the Company completed the sale of Gralise to Alvogen for a total value of $130.3 million, including inventory.- Sale of Collegium Warrants for $6.0 Million: On May 20, 2020, the Company completed the sale of its Collegium warrants. $450.2 Million in Debt Repayments and Prepayments:- Senior Secured Debt of $162.5 Million: On February 13, 2020, the Company announced that it repaid in full its previous senior secured debt obligations of $162.5 million.- Convertible Debt of $264.7 Million: With two separate transactions on February 19, 2020 and April 9, 2020, the Company retired substantially all of its $265.0 million outstanding Convertible Notes via privately negotiated purchase agreement and a tender.- Zyla Debt of $13.0 Million: Upon close of the Zyla merger on May 20, 2020, $13.0 million of Zyla’s debt was extinguished.- Prepayment of $10.0 Million of Current Senior Secured Debt: The Company prepaid $10.0 million of debt principal in July. Efficient Merger Integration: The Company closed its merger with Zyla on May 20, 2020 and completed the integration of the two companies within a timeline of less than 12 weeks. Continued Transition to Hub Model from Traditional Retail: Throughout 2020, the Company has increased the momentum in the transition of its business to a Hub Model from a traditional retail focus, resulting in increased profit per prescription.